Search Results - "Sampi, K"

Malignant lymphoma NHL by Sampi, K

“…The long-term survivors of malignant lymphoma who had been treated in Saitama Cancer Center since September 1976 were evaluated. The primary treatment was…”
Get more information

Stage I malignant lymphoma of Waldeyer's ring: frequent relapse after radiation therapy by Takagi, T, Sampi, K, Iida, K

“…The natural history and therapeutic results of 26 patients with stage I malignant lymphoma of Waldeyer's ring (ML-WR) were analyzed retrospectively. Complete…”
Get more information

Immunoblastic lymphadenopathy-like T cell lymphoma with high levels of serum interleukin-6, cold agglutinin disease, and immune thrombocytopenia by Takayanagi, N, Sampi, K

“…An 88-year-old woman was admitted with generalized lymphadenopathy, anemia, and thrombocytopenia. On admission, a peripheral blood examination showed a red…”
Get more information

Significance of tumor markers in the treatment of cancer: hematologic malignancy by Sampi, K

“…Hematologic malignancies, such as acute leukemia and malignant lymphoma. Respond well to cancer chemotherapy. Therefore, it is important to monitor the state…”
Get more information

Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy by Sampi, K

“…Cancer chemotherapy combined with calcium-channel blockers was administered to seventeen evaluable patients with hematologic malignancy and solid tumor who…”
Get more information

Chemotherapy of malignant lymphoma by Sampi, K

Get more information

A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study by Takagi, T, Sampi, K, Sawada, U, Sakai, C, Oguro, M

“…To evaluate a new combination chemotherapy with mitoxantrone (MXT), etoposide (VP-16), vindesine (VDS), and prednisolone (MEVP therapy) as a front-line…”
Get more information

Pilot late phase II study of KRN8602 (MX2), a novel anthracycline derivative, for acute leukemia--a dose finding study in combination by Hiraoka, A, Sampi, K, Kuraishi, Y, Takemoto, Y, Okabe, K, Tamura, K, Ogawa, M

“…In order to determine the clinically optimal dose of KRN8602, a new anthracycline derivative, in combination therapy for acute leukemia, we performed a pilot…”
Get more information

Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia by Takemoto, Y, Sampi, K, Kuraishi, Y, Toki, H, Tamura, K, Ogawa, M

“…We performed an early phase II study of KRN8602, a new anthracycline derivative for refractory or relapsed acute leukemias. KRN8602 was given at a dose of 15…”
Get more information

Differentiation of human myeloblastic leukemia ML-1 cells into macrophages by staurosporine, an inhibitor of protein kinase activities by Makishima, M, Honma, Y, Hozumi, M, Sampi, K, Motoyoshi, K, Nagata, N, Hattori, M

“…Protein kinase activities are involved in cellular proliferation and differentiation, and inhibitors of these activities are useful for studying the mechanisms…”
Get more information

Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study by Sampi, K, Hattori, M

“…Cefpiramide + amikacin (CPM + AMK) was compared in a prospective randomized trial with our standard regimen of piperacillin plus amikacin (PIPC + AMK) as an…”
Get more information

Phase II study of KRN8602 (MX2) for malignant lymphoma by Okabe, K, Sampi, K, Kuraishi, Y, Takemoto, Y, Tamura, K, Ogawa, M

“…We performed a clinical phase II study of KRN8602, a new anthracycline derivative, for relapsed or recurrent malignant lymphoma. KRN8602 was given at doses of…”
Get more information

Gastrointestinal toxicity induced by anticancer drugs--including new antiemetic drugs by Sampi, K, Taguchi, T

“…In a cross-over design of a study of prevention of emesis induced by cancer chemotherapy done in Saitama Cancer Center, the efficacy of oral lorazepam was…”
Get more information

Intensive carboquone and cryopreserved autologous bone marrow transplantation for relapsed malignancies by Sampi, K, Kuga, T, Makishima, M, Hattori, M

Get more information

A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukemia or autologous bone marrow transplantation: a randomized study by Sampi, K, Maseki, N, Hattori, M

“…Seventy-three patients mainly receiving consolidation therapy for acute leukemia or autologous bone marrow transplantation were studied in a randomized trial…”
Get more information

Similar efficacy of less than 6 and 7-10 courses of therapy with anthracycline-based combination chemotherapy for localized non-Hodgkin's lymphoma of extranodal type by Sampi, K, Takouda, K, Takagi, T, Hattori, M

“…We studied retrospectively the influence on the prognosis of patients with localized non-Hodgkin's lymphoma of extranodal type with regard to the duration of…”
Get more information

Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center by Sampi, K, Sakurai, M, Kaneko, Y, Hattori, M

“…Forty patients with previously untreated acute nonlymphocytic leukemia (ANLL) were treated at Saitama Cancer Center between February 1979 and November 1983…”
Get more information

Epirubicin-based combination chemotherapy in the treatment of non-Hodgkin's lymphoma: with emphasis of elderly patients by Sampi, K, Takouda, K, Hattori, M

“…Twenty-four patients with non-Hodgkin's lymphoma aged 60 years and older were treated with epirubicin-based combination chemotherapy. Complete remission was…”
Get more information

Initial anthracycline-based chemotherapy without radiotherapy in patients older than 70 years with localized lymphoma arising from Waldeyer's ring by Sampi, K, Takagi, T, Morii, K, Hattori, M

“…Between July 1982 and November 1992 twenty-six patients older than 70 years with localized stage of non-Hodgkin's lymphoma (NHL) arising from Waldeyer's ring…”
Get more information

Intensive 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3- nitrosourea hydrochloride (ACNU) and cryopreserved autologous bone marrow transplantation by Sampi, K, Makishima, M, Kuga, T, Yanagawa, S, Hattori, M

“…High-dose ACNU followed by autologous bone marrow transplantation was administered alone or together with other agents such as cyclophosphamide, dacarbazine,…”
Get more information